User login
Key clinical point: Omission of axillary lymph node dissection (ALND) was associated with lymph node understaging but had no impact on systemic therapy recommendations in patients with clinically node-positive breast cancer (cN+ BC).
Major finding: A higher proportion of patients undergoing ALND vs receiving axillary radiotherapy (ART) were detected with ≥ 4 positive nodes (58.9% vs 33.8%). ALND was not associated with the proportion of patients receiving adjuvant chemotherapy after upfront surgery (adjusted odds ratio [aOR] 0.72; 95% CI 0.19-2.67) or systemic therapy after neoadjuvant chemotherapy (aOR 0.86; 95% CI 0.43-1.70).
Study details: Findings are from a prospective, observational cohort study including 500 patients with cN+ BC who underwent tailored axillary surgery and were randomly assigned to undergo ALND or receive ART.
Disclosures: This study was supported by the Swiss State Secretariat for Education, Research and Innovation, and other sources. Some authors declared receiving grants, personal fees, speaker fees, patient fees or having other ties with various sources including the funding source.
Source: Weber WP et al and the TAXIS Study Writing Group . Association of axillary dissection with systemic therapy in patients with clinically node-positive breast cancer. JAMA Surg. 2023 (Jul 19). doi: 10.1001/jamasurg.2023.2840
Key clinical point: Omission of axillary lymph node dissection (ALND) was associated with lymph node understaging but had no impact on systemic therapy recommendations in patients with clinically node-positive breast cancer (cN+ BC).
Major finding: A higher proportion of patients undergoing ALND vs receiving axillary radiotherapy (ART) were detected with ≥ 4 positive nodes (58.9% vs 33.8%). ALND was not associated with the proportion of patients receiving adjuvant chemotherapy after upfront surgery (adjusted odds ratio [aOR] 0.72; 95% CI 0.19-2.67) or systemic therapy after neoadjuvant chemotherapy (aOR 0.86; 95% CI 0.43-1.70).
Study details: Findings are from a prospective, observational cohort study including 500 patients with cN+ BC who underwent tailored axillary surgery and were randomly assigned to undergo ALND or receive ART.
Disclosures: This study was supported by the Swiss State Secretariat for Education, Research and Innovation, and other sources. Some authors declared receiving grants, personal fees, speaker fees, patient fees or having other ties with various sources including the funding source.
Source: Weber WP et al and the TAXIS Study Writing Group . Association of axillary dissection with systemic therapy in patients with clinically node-positive breast cancer. JAMA Surg. 2023 (Jul 19). doi: 10.1001/jamasurg.2023.2840
Key clinical point: Omission of axillary lymph node dissection (ALND) was associated with lymph node understaging but had no impact on systemic therapy recommendations in patients with clinically node-positive breast cancer (cN+ BC).
Major finding: A higher proportion of patients undergoing ALND vs receiving axillary radiotherapy (ART) were detected with ≥ 4 positive nodes (58.9% vs 33.8%). ALND was not associated with the proportion of patients receiving adjuvant chemotherapy after upfront surgery (adjusted odds ratio [aOR] 0.72; 95% CI 0.19-2.67) or systemic therapy after neoadjuvant chemotherapy (aOR 0.86; 95% CI 0.43-1.70).
Study details: Findings are from a prospective, observational cohort study including 500 patients with cN+ BC who underwent tailored axillary surgery and were randomly assigned to undergo ALND or receive ART.
Disclosures: This study was supported by the Swiss State Secretariat for Education, Research and Innovation, and other sources. Some authors declared receiving grants, personal fees, speaker fees, patient fees or having other ties with various sources including the funding source.
Source: Weber WP et al and the TAXIS Study Writing Group . Association of axillary dissection with systemic therapy in patients with clinically node-positive breast cancer. JAMA Surg. 2023 (Jul 19). doi: 10.1001/jamasurg.2023.2840